Chemoradiation combined with immunotherapy significantly boosts survival in patients with resected extrahepatic ...

CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of its generic capecitabine. Capecitabine is a nucleoside ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

Processa Pharmaceuticals, Inc., a clinical-stage company specializing in next-generation cancer therapies, announced the acceptance of three abstracts for presentation at the 2025 American Society ...

The metronomic capecitabine plus AI arm exhibited a median PFS of 20.9 months compared with 11.9 months in the AI arm (hazard ratio [HR] 0.58, 95% CI 0.43-0.76).

Background: Patients (pts) with biliary tract cancer (BTC) still have a poor outcome with limited effective treatment options (only 20% of pts eligible for surgically curative resection, 5-year OS ...

From November 2020 to April 2024, the CASSANDRA PACT-21 trial randomized 260 adults with stage I-III pancreatic cancer at 17 centers in Italy to 4 months of either PAXG (oral daily capecitabine ...

They randomly assigned 748 patients (median age, 59 years; range, 24-75; 69.7% men) to receive capecitabine and oxaliplatin plus either 12 mg daily anlotinib (days 1-14) or 7.5 mg/kg IV ...

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial. JCO Precis Oncol 9 , ...

Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA PR Newswire OXFORD, England and ...